PharmaCom BioVet (Previously ABV Gold) Announces the Corporate Philosophy of PharmaCom BioVet Inc. and Future Expansion Approach
Nov 10, 2010
RALEIGH, NC--(Marketwire - August 15, 2008) - Gary S. Berthold, President and Chief Executive Officer of PharmaCom BioVet Inc., previously ABV Gold, Inc. (PINKSHEETS: ABVG), would like to take this occasion to announce to shareholders the name change of ABV Gold, Inc. to PharmaCom BioVet Inc. Mr. Berthold would like to take this opportunity to announce a comprehensive synopsis of PharmaCom BioVet Inc. and Future Expansion Approach and comments, "The corporate philosophy of PharmaCom BioVet Inc. (PCBV) is to introduce and further develop Bone Marrow Transplantation and other cancer treatment procedures to benefit companion animals (canine and feline) that are diagnosed with lymphoma, other types of cancers, and other diseases.

"With this in mind, PharmaCom BioVet Inc. has established and incorporated working relationships and partnerships with some of the world's top Veterinary Oncologists and Veterinary Cancer Researchers to enable PharmaCom BioVet to bring innovative new treatment procedures to the companion animal healthcare market."

Mr. Berthold continues, "The human-animal bond is extremely strong and continues to grow as many pet owners consider their pets to be family members. This has created an expanding companion animal care marketplace." In the United States alone, it is estimated that companion animal caregivers spend in excess of $52 billion annually on overall companion animal care.

In the Veterinary Oncology care field it is estimated that the annual dollars spent specifically on cancer diagnostics and treatment is substantial and increasing at a significant rate. This level of therapeutic care is provided primarily by using established human cancer therapeutic products and adapting them for animal use.